Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 901–1,000 of 1,026

1. Role of PD-L1 and PD-L2 in allergic diseases and asthma
   Avadhesh Kumar Singh, P. Stock, Omid Akbari · 2010 · Allergy
2. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
   Harshita B. Gupta, Curtis A. Clark, Bin Yuan, Gangadhara R. Sareddy, Srilakshmi Pandeswara, Alvaro Souto Padron, Vincent J. Hurez, Jose Ramon Conejo-Garcia, Ratna K. Vadlamudi, Rong Li et al. · 2016 · Signal Transduction and Targeted Therapy
3. Porphyromonas gingivalis activates NFκB and MAPK pathways in human oral epithelial cells
   Sabine Elisabeth. Groeger, Fabian Jarzina, Eugen Domann, Joerg Meyle · 2017 · BMC Immunology
4. Immune checkpoint dysfunction in large and medium vessel vasculitis
   Ryu Watanabe, Hui Zhang, Gerald J. Berry, Jörg J. Goronzy, Cornelia M. Weyand · 2017 · American Journal of Physiology-Heart and Circulatory Physiology
5. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
   Bingshan Liu, Yongping Song, Delong Liu · 2017 · Journal of Hematology & Oncology
6. The Prognostic and Therapeutic Value of PD-L1 in Glioma
   Ruo Qiao Chen, Feng Liu, Xin Yao Qiu, Xiaoqian Chen · 2019 · Frontiers in Pharmacology
7. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
   Zhong Zheng, Rui Sun, Huijin Zhao, Di Fu, Huijuan Zhong, Xiangqin Weng, Bin Qu, Yan Fang Zhao, Li Wang, Weili Zhao · 2019 · Molecular Cancer
8. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
   Naoya Maekawa, Satoru Konnai, Maki Nishimura, Yumiko Kagawa, Satoshi Takagi, Kenji Hosoya, Hiroshi Ohta, Sangho Kim, Tomohiro Okagawa, Yusuke Izumi et al. · 2021 · npj Precision Oncology
9. Vascular Normalization: A New Window Opened for Cancer Therapies
   Ting Yang, Hongqi Xiao, Xiaoxia Liu, Zhihui Wang, Qingbai Zhang, Nianjin Wei, Xinggang Guo · 2021 · Frontiers in Oncology
10. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation
    Yingying Shen, Chaojie Lu, Zhengbo Song, Chenxiao Qiao, Jiaoli Wang, Jinbiao Chen, Chengyan Zhang, Xianchang Zeng, Zeyu Ma, Tao Chen et al. · 2022 · Nature Communications
11. Targeted therapy for non-small-cell lung cancer: past, present and future
    Patrick M. Forde, David S. Ettinger · 2013 · Expert Review of Anticancer Therapy
12. Immune checkpoint inhibitors in advanced non–small cell lung cancer
    Hazem I. Assi, Alice Oliffson Kamphorst, Nour M. Moukalled, Suresh S. Ramalingam · 2017 · Cancer
13. Antibody and antibody fragments for cancer immunotherapy
    Weizhi Chen, Yuan Yang, Xiqun Jiang · 2020 · Journal of Controlled Release
14. Drug discovery is an eternal challenge for the biomedical sciences
    Hua Li, Wenyi Wei, Hong‐Xi Xu · 2022 · Acta Materia Medica
15. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
    Kevin Wang, Paulina Coutifaris, David Brocks, Guanning Wang, Tarek Azar, Sabrina Solis, Ajeya Nandi, Shaneaka Anderson, Nicholas A. Han, Sasikanth Manne et al. · 2024 · Cancer Cell
16. PD‐1/B7‐H1 Interaction Contribute to the Spontaneous Acceptance of Mouse Liver Allograft
    Miwa Morita, Masayuki Fujino, G. Jiang, Y. Kitazawa, Lin Xie, Miyuki Azuma, Hideo Yagita∥, Shizuko Nagao, Atsushi Sugioka, Yoshikazu Kurosawa et al. · 2009 · American Journal of Transplantation
17. Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
    Alan G. Ramsay · 2013 · British Journal of Haematology
18. TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination
    Vesna Pulko, Xin Liu, Christopher J. Krco, Kimberley J Harris, Xavier Frigola, Eugene D. Kwon, Haidong Dong · 2009 · The Journal of Immunology
19. Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications inDe novoAcute Myeloid Leukemia
    Hideto Tamura, Kazuo Dan, Koji Tamada, Kyoko Nakamura, Yumiko Shioi, Hideya Hyodo, Sheng-Dian Wang, Haidong Dong, Lieping Chen, Kíyoyuki Ogata · 2005 · Clinical Cancer Research
20. Recent advances in the clinical development of immune checkpoint blockade therapy
    Atefeh Ghahremanloo, Arash Soltani, Seyed Mohamad Sadegh Modaresi, Seyed Isaac Hashemy · 2019 · Cellular Oncology
21. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses
    Shengdian Wang, Lieping Chen · 2004 · Microbes and Infection
22. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model
    Masatomo Miura · 2009 · International Journal of Oncology
23. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Woo Young Sun, Yu Kyung Lee, Ja Seung Koo · 2016 · Journal of Translational Medicine
24. Pretreatment lymphocyte‐to‐monocyte ratio as an independent prognostic factor for head and neck cancer
    Satoshi Kano, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Tomohiro Sakashita, Tomohiko Kakizaki, Satoshi Fukuda · 2016 · Head & Neck
25. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
    Anshika Bakshi, Sandeep C. Chaudhary, Mehtab Rana, Craig A. Elmets, Mohammad Athar · 2017 · Molecular Carcinogenesis
26. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
    Paris Kosti, John F. Maher, James N. Arnold · 2018 · Frontiers in Immunology
27. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
    Zihai Li, Wenru Song, Mark P. Rubinstein, Delong Liu · 2018 · Journal of Hematology & Oncology
28. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
    Linlin Sun, Ri‐Yao Yang, Chia-Wei Li, Mei‐Kuang Chen, Bin Shao, Jung-Mao Hsu, Li-Chuan Chan, Yi Yang, Jennifer L. Hsu, Yun‐Ju Lai et al. · 2018 · Europe PMC (PubMed Central)
29. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
    Wu, Youqian, Zhang, Chao, Liu, Xiaolan, He, Zhengfu, Shan, Bing, Zeng, Qingxin, Zhao, Qingwei, Zhu, Huaying, Liao, Hongwei, Cen, Xufeng et al. · 2021 · Nature Communications
30. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
    Lei Geng, Dongsheng Huang, Junwei Liu, Yigang Qian, Junfang Deng, Donglin Li, Zhenhua Hu, Jian Zhang, Guoping Jiang, Shusen Zheng · 2008 · Journal of Cancer Research and Clinical Oncology
31. Immune evasion in acute myeloid leukemia: current concepts and future directions
    Ryan M. Teague, Justin Paul Kline · 2013 · Journal for ImmunoTherapy of Cancer
32. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications
    Ilinca Popp, Anca‐Ligia Grosu, Gabriele Niedermann, Dan Gabriel Duda · 2016 · Radiotherapy and Oncology
33. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
    Poonam K. Panjwani, Vivek Charu, Monique DeLisser, Hernan F. Molina-Kirsch, Yasodha Natkunam, Shuchun Zhao · 2017 · Human Pathology
34. Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1–5 and Superoxide Dismutase 1–3 Signal Transduction Pathways
    Alessia Parascandolo, Mikko O. Laukkanen · 2018 · Antioxidants and Redox Signaling
35. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Tianyu Wang, Xiaoxing Wu, Changying Guo, Kuojun Zhang, Jinyi Xu, Zheng Li, Sheng Jiang · 2018 · Journal of Medicinal Chemistry
36. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation
    Zhiwei Fan, Changyue Wu, Miaomiao Chen, Yongying Jiang, Yuanyuan Wu, Renfang Mao, Yihui Fan · 2021 · Acta Pharmaceutica Sinica B
37. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity
    Julia Joung, Paul C. Kirchgatterer, Ankita Singh, Jang Hwan Cho, Suchita P. Nety, Rebecca C. Larson, Rhiannon K. Macrae, Rebecca Deasy, Yuen‐Yi Tseng, Marcela Valderrama Maus et al. · 2022 · Nature Communications
38. Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
    Cubillos-Zapata, Carolina, Avendaño-Ortiz, Jose, Hernandez-Jimenez, Enrique, Toledano, Victor, Casas-Martin, Jose, Varela-Serrano, Anibal, Torres, Marta, Almendros, Isaac, Casitas, Raquel, Fernández-Navarro, Isabel et al. · 2017 · European Respiratory Journal
39. Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
    Naoya Maekawa, Satoru Konnai, Ryoyo Ikebuchi, Tomohiro Okagawa, Mami Adachi, Satoshi Takagi, Yumiko Kagawa, Chie Nakajima, Yasuhiko Suzuki, Shiro Murata et al. · 2014 · PLoS ONE
40. ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
    Francesco Torino, Agnese Barnabei, Rosa Maria Paragliola, Paolo Marchetti, Roberto Salvatori, Salvatore Maria Corsello · 2013 · European Journal of Endocrinology
41. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
    Yusuke Inoue, Katsuhiro Yoshimura, Kazutaka Mori, Nobuya Kurabe, Tomoaki Kahyo, Hiroki Mori, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Naoki Inui et al. · 2016 · Oncotarget
42. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
    Jacalyn M. Rosenblatt, David Avigan · 2016 · Blood
43. Merkel Cell Polyomavirus and Merkel Cell Carcinoma
    Valeria Pietropaolo, Carla Prezioso, Ugo Lionel Moens · 2020 · Cancers
44. Evasive Strategies in Rabies Virus Infection
    Monique Lafon · 2011 · Advances in virus research
45. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
    Bai, Xue, Fisher, David E., Flaherty, Keith T. · 2019 · Nature Reviews Clinical Oncology
46. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice
    Zhao, Wenxiu, Zhang, Lei, Yin, Zhenyu, Su, Weixue, Ren, Guangli, Zhou, Changsheng, You, Junyong, Fan, Jia, Wang, Xiaomin · 2011 · International Journal of Cancer
47. Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy
    Orin G. Bloch, Michael K. Lim, Michael E. Sughrue, Ricardo J. Komotar, John Matthew Abrahams, Donald M. O’Rourke, Anthony L. D’Ambrosio, Jeffrey N. Bruce, Andrew T. Parsa · 2017 · Clinical Cancer Research
48. Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
    Elena Burova, Aynur Hermann, Janelle C. Waite, Terra B. Potocky, Venus Ka-Man Lai, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Qi Wu et al. · 2017 · Molecular Cancer Therapeutics
49. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
    J. Wang, Yunlong Jia, S Zhao, Xiaoling Zhang, Xuhan Wang, Xiaonan Han, Yuqing Wang, Mian Ma, Jiaqi Shi, Longtao Liu · 2017 · Oncogene
50. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
    Joseph D. DiDomenico, Jonathan Balquiedra Lamano, Daniel Eduardo Oyon, Yuping Li, Dorina Veliceasa, Gurvinder Kaur, Leonel Ampie, Winward Choy, Jason B. Lamano, Orin G. Bloch · 2018 · OncoImmunology
51. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair–Deficient Colorectal Cancer by Targeting PD-L1
    Mai Ashizawa, Hirokazu Okayama, Teruhide Ishigame, Aung Kyi Thar Min, Katsuharu Saito, Daisuke Ujiie, Yuko Murakami, Tomohiro Kikuchi, Yuko Nakayama, Masaru Noda et al. · 2019 · Molecular Cancer Research
52. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function
    Amy J. Petty, Rui Dai, Rosa Lapalombella, Robert A. Baiocchi, Don M. Benson, Zihai Li, Xiaopei Huang, Yiping Yang · 2021 · JCI Insight
53. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
    Kriegsman, Barry A, Vangala, Pranitha, Chen, Benjamin J, Meraner, Paul, Brass, Abraham L, Garber, Manuel, Rock, Kenneth L · 2019 · The Journal of Immunology
54. Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer
    Yaxiong Zhang, Shiyang Kang, Jianfei Shen, Jiaxi He, Long Jiang, Wei Wang, Zhihua Guo, Guilin Peng, Gang Chen, Jianxing He et al. · 2015 · Medicine
55. Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
    Maria Anna Smolle, Horatiu N. Calin, Martin Pichler, George A. Călin · 2017 · FEBS Journal
56. CAR T‐cell therapy for pancreatic cancer
    Carl J. DeSelm, Zachary E. Tano, Anna M. Varghese, Prasad S. Adusumilli · 2017 · Journal of Surgical Oncology
57. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
    Tim Müller, Martin Braun, Dimo Dietrich, Seher Aktekin, Simon Höft, Glen Kristiansen, Friederike Göke, Andreas Schröck, Johannes Brägelmann, Stefanie Andrea Erika Held et al. · 2017 · Oncotarget
58. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
    Laura Chiossone, Margaux Vienne, Yann M. Kerdiles, Éric Vivier · 2017 · Seminars in Immunology
59. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
    Ming Li, Anqi Li, Shuling Zhou, Yan Kang Xu, Yaoxing Xiao, Rui Bi, Wentao Yang · 2018 · BMC Cancer
60. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
    Chaoqun Liu, Jing Xu, Zhongguo Zhou, Li-Lian Jin, Xing-Juan Yu, Gang Xiao, Jie Lin, Shi‐Mei Zhuang, Yaojun Zhang, Limin Zheng · 2018 · British Journal of Cancer
61. Evaluating CAR‐T Cell Therapy in a Hypoxic 3D Tumor Model
    Yuta Ando, Elizabeth L. Siegler, Hoang P. Ta, Gunce E. Cinay, Hao Zhou, Kimberly A. Gorrell, Hannah Au, Bethany M. Jarvis, Pin Wang, Keyue Shen · 2019 · Advanced Healthcare Materials
62. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma
    Yiwei Wang, Hang Wang, Qi Zhao, Yu Xia, Xiaoyi Hu, Jianming Guo · 2015 · Medical Oncology
63. Differential Association of Programmed Death-1 and CD57 with Ex Vivo Survival of CD8+ T Cells in HIV Infection
    Constantinos Petrovas, Benjamin Chaon, David R. Ambrozak, David A. Price, J. Joseph Melenhorst, Brenna J. Hill, Christof Geldmacher, Joseph Paul Casazza, Pratip K. Chattopadhyay, Mario Roederer et al. · 2009 · The Journal of Immunology
64. PD-1/PD-L pathway and autoimmunity
    Taku Okazaki, Jian Wang · 2005 · Autoimmunity
65. Immunotherapy in the treatment of non-small cell lung cancer
    Raghav Sundar, Richie Soong, Byoung Chul Cho, Julie Renee Brahmer, Ross Andrew Soo · 2014 · Lung Cancer
66. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies
    Michael Rückert, Lisa Deloch, Rainer Fietkau, Benjamin Frey, Markus Hecht, Udo S. Gaipl · 2018 · Strahlentherapie und Onkologie
67. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells
    Junyu Xiang, Ni Zhang, Hui Sun, Li Su, Chengcheng Zhang, Huailong Xu, Juan Feng, Meiling Wang, Jun Chen, Limei Liu et al. · 2019 · Gastroenterology
68. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy
    Neeraj Lal, Andrew David Beggs, Benjamin E. Willcox, Gary Middleton · 2015 · OncoImmunology
69. Cancer stem cells and immunoresistance: clinical implications and solutions.
    Jordi Codony‐Servat, Rafael Rosell · 2015 · PubMed Central
70. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
    Yu Yao, Feifei Luo, Chao Tang, Dikang Chen, Zhiyong Qin, Wei Hua, Ming Xu, Ping Zhong, Shuangquan Yu, Di Chen et al. · 2018 · Cancer Immunology Immunotherapy
71. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
    Matthew Kraman, Mustapha Faroudi, Natalie L. Allen, Katarzyna Kmiecik, Daniel Gliddon, Claire J. Seal, Alexander Koers, Mateusz M. Wydro, Sarah Batey, Julia Winnewisser et al. · 2020 · Clinical Cancer Research
72. Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases
    Houssam Aheget, Loubna Mazini, Francisco Martı́n, Boutaïna Belqat, Juan Antonio Marchal, Karim Benabdellah · 2020 · Cancers
73. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
    Cecile A. W. Geuijen, Paul J. Tacken, Liang-Chuan Wang, Rinse Klooster, Pieter Fokko van Loo, Jing Zhou, Arpita Mondal, Yao-Bin Liu, Arjen Kramer, Thomas Condamine et al. · 2021 · Nature Communications
74. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
75. The role of biomarkers in personalized immunotherapy
    Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen · 2022 · Biomarker Research
76. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma
    Masahiro Kikuchi, David A. Clump, Raghvendra Mohan Srivastava, Lingyi Sun, Dexing Zeng, Julio Alexander Díaz-Pérez, Carolyn J. Anderson, Wilson Barry Edwards, Robert Louis Ferris · 2017 · OncoImmunology
77. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis
    Constantinos Roufas, Dimitrios Chasiotis, Anestis Makris, Christodoulos Efstathiades, Christos Dimopoulos, Apostolos Zaravinos · 2018 · Frontiers in Oncology
78. Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs
    Kateryna Volodymyrivna Laikova, Volodymyr Volodymyrovych Oberemok, Alisa M. Krasnodubets, Nikita V. Gal’chinsky, Refat Z. Useinov, Ilya A. Novikov, Zenure Z. Temirova, Горлов Михаил Владимирович, Nikita A. Shved, Vadim Vladimirovich Kumeiko et al. · 2019 · Molecules
79. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
    Joal D. Beane, Gary Lee, Zhili Zheng, Matthew C. Mendel, Daniel Abate‐Daga, Mini Bharathan, Mary A. Black, Nimisha H. Gandhi, Zhiya Yu, Smita S. Chandran et al. · 2015 · Molecular Therapy
80. Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
    Kanchan Kantekure, Yusong Yang, Puthiyaveettil N. Raghunath, András Schaffer, Anders Woetmann, Qian Zhang, Niels Ødum, Mariusz A. Wasik · 2011 · American Journal of Dermatopathology
81. Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells
    Christian U. Blank, Ian Brown, Reinhard Marks, Hiroyuki Nishimura, Tasuku Honjo, Thomas Frank Gajewski · 2003 · The Journal of Immunology
82. Immune escape mechanisms of intraocular tumors
    Jérry Y. Niederkorn · 2009 · Progress in Retinal and Eye Research
83. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
    Michael A. Postow, Parisa Momtaz · 2014 · Pharmacogenomics and Personalized Medicine
84. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
    Anja Derer, Lisa Deloch, Yvonne Rubner, Rainer Fietkau, Benjamin Frey, Udo S. Gaipl · 2015 · Frontiers in Immunology
85. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
    Rika Fujii, Eitan R. Friedman, Jacob Richards, Kwong Yok Tsang, Christopher Ryan Heery, Jeffrey Schlom, James W. Hodge · 2016 · Oncotarget
86. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
    Nayoung Kim, Hun Sik Kim · 2018 · Frontiers in Immunology
87. Basis of PD1/PD-L1 Therapies
    Barbara Seliger · 2019 · Journal of Clinical Medicine
88. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
    Xinwei Qiao, Jian Dong Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin‐hua Liang, Ya‐ling Tang · 2020 · Frontiers in Immunology
89. The Immune System and Cancer
    David Loose, Christophe Van de Wiele · 2009 · Cancer Biotherapy and Radiopharmaceuticals
90. PD-1 regulates extrathymic regulatory T-cell differentiation
    Chen, Xiufen, Fosco, Dominick, Kline, Douglas E., Meng, Liping, Nishi, Saki, Savage, Peter A., Kline, Justin · 2014 · European Journal of Immunology
91. Characterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model
    Lee, Sharon Wei Ling, Adriani, Giulia, Ceccarello, Erica, Pavesi, Andrea, Tan, Anthony Tanoto, Bertoletti, Antonio, Kamm, Roger Dale, Wong, Siew Cheng · 2018 · Frontiers in Immunology
92. Harnessing the Power of the Immune System Via Blockade of PD-1 and PD-L1: A Promising New Anticancer Strategy
    Kim A. Reiss, Patrick M. Forde, Julie Renee Brahmer · 2014 · Immunotherapy
93. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
    Jason Madore, Dario Strbenac, Ricardo E. Vilain, Alexander Maxwell Menzies, Jean Yee Hwa Yang, John F. Thompson, Georgina Venetia Long, Graham J. Mann, Richard A. Scolyer, James S. Wilmott · 2016 · Clinical Cancer Research
94. PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
    Jun Wang, Ruirong Yuan, Wenru Song, Jingwei Sun, Delong Liu, Zihai Li · 2017 · Journal of Hematology & Oncology
95. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
    Mee Y. Bartee, Katherine M. Dunlap, Eric Bartee · 2017 · Cancer Research
96. PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene
    Kristin Berger, Jeffrey J. Pu · 2017 · Gene
97. Putting the Immunologic Brakes on Cancer
    Jedd D. Wolchok · 2018 · Cell
98. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis
    Hanlu Ding, Xiongfei Wu, Wenda Gao · 2005 · Clinical Immunology
99. Human muscle cells express a B7‐related molecule, B7‐H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies
    Heinz Wiendl, Meike Mitsdoerffer, Dagmar Schneider, Lieping Chen, Hanns Lochmüller, Arthur Melms, Michael Weller · 2003 · The FASEB Journal
100. The emerging role of immune checkpoint inhibition in malignant lymphoma
     Ida Hude, Stephanie Sasse, Andreas Engert, Paul Jan Bröckelmann · 2016 · Haematologica